(Q42922740)

11 November 2017

title

Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion (English)

1 reference

11 November 2017

Young Joon Park

1

1 reference

11 November 2017

Hyoung-Kyu Lee

2

1 reference

11 November 2017

Young Bin Im

3

1 reference

11 November 2017

Wonjae Lee

4

1 reference

11 November 2017

Hyo-Kyung Han

5

1 reference

11 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20803127

3 July 2024

publication date

28 August 2010

1 reference

full work available at URL

11 November 2017

http://link.springer.com/content/pdf/10.1007/s12272-010-0814-0.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

http://link.springer.com/article/10.1007/s12272-010-0814-0/fulltext.html

3 July 2024

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

http://link.springer.com/content/pdf/10.1007/s12272-010-0814-0

3 July 2024

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Archives of Pharmacal Research

3 July 2024

published in

1 reference

11 November 2017

volume

33

1 reference

11 November 2017

issue

8

1 reference

11 November 2017

page(s)

1235-1240

1 reference

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12272-010-0814-0

Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers.

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions

3 July 2024

3

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

A review of poloxamer 407 pharmaceutical and pharmacological characteristics.

3 July 2024

5

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man

3 July 2024

6

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Preparation of a solid dispersion of felodipine using a solvent wetting method

3 July 2024

7

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Improving drug solubility for oral delivery using solid dispersions

3 July 2024

8

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Enhancement of solubility, dissolution and bioavailability of ibuprofen in solid dispersion systems

3 July 2024

11

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Evaluation of SLS: APG mixed surfactant systems as carrier for solid dispersion.

3 July 2024

12

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Design of pH-independent controlled release matrix tablets for acidic drugs

3 July 2024

13

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations.

3 July 2024

14

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate

3 July 2024

15

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release

3 July 2024

16

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs

3 July 2024

17

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

Gastric acidity-dependent bioavailability of commercial sustained release preparations of indomethacin, evaluated by gastric acidity-controlled beagle dogs

3 July 2024

18

1 reference

https://api.crossref.org/works/10.1007/S12272-010-0814-0

3 July 2024

Identifiers

1 reference

Dimensions Publication ID

11 November 2017

1019233420

0 references

1 reference